Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
0910-0001
ICR Reference No:
201407-0910-014
Status:
Historical Active
Previous ICR Reference No:
201104-0910-006
Agency/Subagency:
HHS/FDA
Agency Tracking No:
CDER
Title:
FDA Approval to Market a New Drug
Type of Information Collection:
No material or nonsubstantive change to a currently approved collection
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved without change
Conclusion Date:
08/21/2014
Retrieve Notice of Action (NOA)
Date Received in OIRA:
07/22/2014
Terms of Clearance:
Prior terms remain in effect: In accordance with 5 CFR 1320, the collection is approved. However, the agency is reminded that approvals by OMB only extend to the information described in the supporting statement. By the time of the next submission, FDA must ensure that the request for the approval of Form 356H fully describes the circumstances for which it will be used - including the information described in the supporting statement that is relevant to 356H. Alternatively, FDA may request approval in this information collection.
Inventory as of this Action
Requested
Previously Approved
Expiration Date
09/30/2014
09/30/2014
09/30/2014
Responses
70,315
0
70,315
Time Burden (Hours)
3,466,039
0
3,466,039
Cost Burden (Dollars)
0
0
0
Abstract:
This information collection request captures the requirements of Section 505 of the Food, Drug, and Cosmetic Act, which requires that a new drug may not be marketed unless the manufacture provides FDA with scientific evidence that the drug is both safe and effective. The regulations at 21 CFR Part 314 provide the means through which pharmaceutical manufacturers can obtain FDA approval of a drug product marketing application, and the means through which FDA can assure the safety and effectiveness of the marketed products.
Authorizing Statute(s):
None
Citations for New Statutory Requirements:
None
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
Not associated with rulemaking
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
75 FR 79001
12/17/2010
30-day Notice:
Federal Register Citation:
Citation Date:
76 FR 20680
04/13/2011
Did the Agency receive public comments on this ICR?
No
Number of Information Collection (IC) in this ICR:
23
IC Title
Form No.
Form Name
314.101(a)
314.107(c)
314.107(e)
314.107(f)
314.110(a)(5)
314.110(c)
314.420
314.50 (a), (b), (c), (d), (e), (f), and (k)
3331
NDA-Field Alert Report
314.50(i) and 314.94(a)(12)
314.50(j)
314.52 and 314.95
314.60
314.65
314.70 and 314.71
314.72
314.81(b)(1) [3331]
314.81(b)(2) [2252]
314.81(b)(3)(i) [2253]
314.94(a)(1)-(11) and (d)
314.96
314.97
314.99(a)
Guidance; Reports on the Status of Postmarketing Studies/Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
70,315
70,315
0
0
0
0
Annual Time Burden (Hours)
3,466,039
3,466,039
0
0
0
0
Annual Cost Burden (Dollars)
0
0
0
0
0
0
Burden increases because of Program Change due to Agency Discretion:
No
Burden Increase Due to:
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
Annual Cost to Federal Government:
$212,090,000
Does this IC contain surveys, censuses, or employ statistical methods?
No
Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002?
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
No
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
Uncollected
Agency Contact:
Ila Mizrachi 301 796-7726 ila.mizrachi@fda.hhs.gov
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
07/22/2014
An official website of the United States government
The .gov means it's official.
The site is secure.
